Skip to Content

Accretropin Approval History

Accretropin (somatropin (rDNA origin)) is recombinant human growth hormone indicated for treatment of pediatric patients who have growth failure due to an inadequate secretion of normal endogenous growth hormone, or treatment of short stature associated with Turner Syndrome in pediatric patients whose epiphyses are not closed.

Development History and FDA Approval Process for Accretropin

Jan 25, 2008Approval Cangene's Recombinant Human Growth Hormone Accretropin Approved by the U.S. Food and Drug Administration
Mar 12, 2007Cangene Receives an Approvable Letter From the FDA for Human Growth Hormone
Jul 17, 2006Cangene’s Human Growth Hormone Drug Submission is Accepted for Review by FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.